Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study (original) (raw)

CNS spectrums, 2017

Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy

LESLIE CITROME

Advances in Therapy, 2013

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Marc Debelle

International clinical psychopharmacology, 2017

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Alessandro Cuomo

Annals of General Psychiatry, 2020

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

BMC Psychiatry, 2017

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety

Advances in Therapy, 2021

Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies

European Neuropsychopharmacology, 2018

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial

Schizophrenia Research, 2014

The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials

CNS Spectrums, 2021

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

LESLIE CITROME

Neuropsychiatric Disease and Treatment, 2018

Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist

LESLIE CITROME

Clinical Schizophrenia & Related Psychoses, 2016

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms

Octavian Vasiliu

Frontiers in Psychiatry, 2021

Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial

The Journal of clinical psychiatry, 2015

Cariprazine in the treatment of schizophrenia

International Clinical Psychopharmacology, 2016

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

Schizophrenia research, 2016

Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives

Swaran Preet Singh

Future Neurology, 2020

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment

Alexey Pavlichenko

Consortium Psychiatricum, 2020

The preclinical discovery and development of cariprazine for the treatment of schizophrenia

Marcin Kołaczkowski

Expert Opinion on Drug Discovery, 2018

Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia

Elmars Rancans

Frontiers in Psychiatry, 2022

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies

Barbara Sebe

Neuropsychiatric Disease and Treatment

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence

European Psychiatry

The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors

European Psychiatry, 2019

Symptomatic Profi le of Cariprazine in the Context of ICD-11 Domains for Schizophrenia: Review of Clinically Oriented Studies

Alexey Pavlichenko

2022

Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series

Juan David Duque Yemail

Neuropsychiatric Disease and Treatment

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine

Borjanka Batinić

Frontiers in Psychiatry, 2021

Effect of cariprazine on the 6 domains of schizophrenia in ICD-11: a narrative review

Alexey Pavlichenko

Consortium Psychiatricum, 2022

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania

Julie Passarell

Clinical and Translational Science, 2019

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

Lancet (London, England), 2017

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?

Gavin Reynolds

J Psychopharmacol, 2021

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/ D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

Zsolt Némethy

Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials

Frank Besag

CNS drugs, 2016

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis

Robert Litman

International journal of clinical practice, 2017